Zhao Y, Gao Y, Petnak T, Cheungpasitporn W, Thongprayoon C, Zhang X
Respir Res. 2022; 23(1):164.
PMID: 35729565
PMC: 9215101.
DOI: 10.1186/s12931-022-02082-x.
Zamanian R, Badesch D, Chung L, Domsic R, Medsger T, Pinckney A
Am J Respir Crit Care Med. 2021; 204(2):209-221.
PMID: 33651671
PMC: 8650794.
DOI: 10.1164/rccm.202009-3481OC.
Atienza-Mateo B, Remuzgo-Martinez S, Prieto-Pena D, Mora Cuesta V, Iturbe-Fernandez D, Llorca J
J Clin Med. 2020; 9(10).
PMID: 32977717
PMC: 7598697.
DOI: 10.3390/jcm9103070.
Misra D, Ahmed S, Agarwal V
Rheumatol Int. 2020; 40(5):679-694.
PMID: 31960079
DOI: 10.1007/s00296-020-04515-6.
Distler J, Gyorfi A, Ramanujam M, Whitfield M, Konigshoff M, Lafyatis R
Nat Rev Rheumatol. 2019; 15(12):705-730.
PMID: 31712723
DOI: 10.1038/s41584-019-0322-7.
Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte A, Cordeiro A, Fernandes B, Bernardes M, Martins P, Cordeiro I
Clin Rheumatol. 2019; 38(7):2001-2009.
PMID: 31016581
DOI: 10.1007/s10067-019-04557-7.
Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.
Melissaropoulos K, Liossis S
Rheumatol Int. 2018; 38(7):1225-1234.
PMID: 29869007
DOI: 10.1007/s00296-018-4076-3.
Current perspective on rituximab in rheumatic diseases.
Schioppo T, Ingegnoli F
Drug Des Devel Ther. 2017; 11:2891-2904.
PMID: 29042750
PMC: 5633295.
DOI: 10.2147/DDDT.S139248.
Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis.
de Bourcy C, Dekker C, Davis M, Nicolls M, Quake S
Sci Immunol. 2017; 2(15).
PMID: 28963118
PMC: 5800854.
DOI: 10.1126/sciimmunol.aan8289.
Rituximab in early systemic sclerosis.
Boonstra M, Meijs J, Dorjee A, Ajmone Marsan N, Schouffoer A, Ninaber M
RMD Open. 2017; 3(2):e000384.
PMID: 28879049
PMC: 5574444.
DOI: 10.1136/rmdopen-2016-000384.
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann E, Tashkin D
Ann Am Thorac Soc. 2016; 13(11):2045-2056.
PMID: 27560196
PMC: 5122482.
DOI: 10.1513/AnnalsATS.201606-426FR.
Challenges and opportunities in treating inflammation associated with pulmonary hypertension.
Voelkel N, Tamosiuniene R, Nicolls M
Expert Rev Cardiovasc Ther. 2016; 14(8):939-51.
PMID: 27096622
PMC: 5085832.
DOI: 10.1080/14779072.2016.1180976.
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis.
Yasuoka H
Clin Med Insights Circ Respir Pulm Med. 2016; 9(Suppl 1):97-110.
PMID: 26819563
PMC: 4720185.
DOI: 10.4137/CCRPM.S23315.
Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.
Iqbal K, Kelly C
Ther Adv Musculoskelet Dis. 2015; 7(6):247-67.
PMID: 26622326
PMC: 4637848.
DOI: 10.1177/1759720X15612250.
Efficacy and safety of rituximab in rheumatic diseases.
Rath E, Zwerina J, Oppl B, Nell-Duxneuner V
Wien Med Wochenschr. 2015; 165(1-2):28-35.
PMID: 25676699
DOI: 10.1007/s10354-014-0331-8.
Systemic sclerosis-associated pulmonary arterial hypertension.
Chaisson N, Hassoun P
Chest. 2013; 144(4):1346-1356.
PMID: 24081346
PMC: 3787920.
DOI: 10.1378/chest.12-2396.
Immunosuppression for interstitial lung disease in systemic sclerosis.
Cappelli S, Guiducci S, Bellando Randone S, Cerinic M
Eur Respir Rev. 2013; 22(129):236-43.
PMID: 23997050
PMC: 9487355.
DOI: 10.1183/09059180.00001813.
Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.
Vij R, Strek M
Chest. 2013; 143(3):814-824.
PMID: 23460159
PMC: 3590889.
DOI: 10.1378/chest.12-0741.
Rituximab-induced regression of CREST-related calcinosis.
de Paula D, Klem F, Lorencetti P, Muller C, Azevedo V
Clin Rheumatol. 2012; 32(2):281-3.
PMID: 23179007
DOI: 10.1007/s10067-012-2124-z.
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence.
Daoussis D, Liossis S, Yiannopoulos G, Andonopoulos A
Int J Rheumatol. 2011; 2011:214013.
PMID: 21826145
PMC: 3150146.
DOI: 10.1155/2011/214013.
